, of collaborators form the Jean Verdier Study Group and their affiliations: Erwan Guyot 1,2 , Angela Sutton 1,2 , Valérie Bourcier 3 , Véronique Grando 3 , Marianne Ziol 4,5 , Nathalie Charnaux 1,2 , Michel Beaugrand 3,6 , Pierre Nahon 3,6 , and Nathalie Ganne-Carrié 3, vol.6

U. Smbh/inserm, . U1148, and F. Bobigny,

, University Paris 13-UFR SMBH/INSERM, U1162, Génomique fonctionnelle des Tumeurs solides, CRB des hôpitaux universitaires PSSD, vol.5

, Members of the Swiss Hepatitis C Cohort Study Group, Marc Bourlière (Marseilles), Ioannis Theodorou (Paris)

J. Bruix, M. Reig, and M. Sherman, Evidence-based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma, Gastroenterology, 2016.

H. B. El-serag, Hepatocellular carcinoma, N Engl J Med, vol.365, pp.1118-1127, 2011.

E. Bah, M. P. Carrieri, P. Hainaut, Y. Bah, O. Nyan et al., 20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia, West Africa. PLoS One, vol.8, p.75775, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01261767

Q. Peng, S. Li, X. Lao, Z. Chen, R. Li et al., Association Between XPD Lys751Gln and Asp312Asn Polymorphisms and Hepatocellular Carcinoma Risk: A Systematic Review And Meta-Analysis, Medicine (Baltimore), vol.93, p.330, 2014.

I. Hinrichsen, M. Kemp, J. Peveling-oberhag, S. Passmann, G. Plotz et al., Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs, PLoS One, vol.9, p.84453, 2014.

M. M. Kirstein and A. Vogel, The pathogenesis of hepatocellular carcinoma, Dig Dis, vol.32, pp.545-553, 2014.

J. S. Lim, S. H. Park, and K. L. Jang, Hepatitis C virus Core protein overcomes stress-induced premature senescence by downregulating p16 expression via DNA methylation, Cancer Lett, vol.321, pp.154-161, 2012.

S. Matsukura, H. Soejima, T. Nakagawachi, H. Yakushiji, A. Ogawa et al., CpG methylation of MGMT and hMLH1 promoter in hepatocellular carcinoma www.impactjournals.com/oncotarget associated with hepatitis viral infection, Br J Cancer, vol.88, pp.521-529, 2003.

E. Limagne, V. Cottet, A. K. Cotte, S. Hamza, P. Hillon et al., Potential role of oxidative DNA damage in the impact of PNPLA3 variant (rs 738409 C>G) in hepatocellular carcinoma risk, Hepatology, vol.60, pp.1110-1111, 2014.

C. J. Chen and D. S. Chen, Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology, Hepatology, vol.36, pp.1046-1049, 2002.

F. Liu, B. Li, Y. Wei, L. Yan, T. Wen et al., XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a meta-analysis, Liver Int, vol.31, pp.802-809, 2011.

X. D. Long, D. Zhao, C. Wang, X. Y. Huang, J. G. Yao et al., Genetic polymorphisms in DNA repair genes XRCC4 and XRCC5 and aflatoxin B1-related hepatocellular carcinoma, Epidemiology, vol.24, pp.671-681, 2013.

T. Sakamoto, Y. Higaki, M. Hara, M. Ichiba, M. Horita et al., hOGG1 Ser326Cys polymorphism and risk of hepatocellular carcinoma among Japanese, J Epidemiol, vol.16, pp.233-239, 2006.

X. D. Long, Y. Ma, Y. P. Wei, and Z. L. Deng, The polymorphisms of GSTM1, GSTT1, HYL1*2, and XRCC1, and aflatoxin B1-related hepatocellular carcinoma in Guangxi population, China. Hepatol Res, vol.36, pp.48-55, 2006.

M. Kiran, R. Saxena, Y. K. Chawla, and J. Kaur, Polymorphism of DNA repair gene XRCC1 and hepatitis-related hepatocellular carcinoma risk in Indian population, Mol Cell Biochem, vol.327, pp.7-13, 2009.

X. D. Long, Y. Ma, Y. F. Zhou, A. M. Ma, and G. H. Fu, Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population, Hepatology, vol.52, pp.1301-1309, 2010.

R. Li, Y. Yang, Y. An, Y. Zhou, Y. Liu et al., Genetic polymorphisms in DNA double-strand break repair genes XRCC5, XRCC6 and susceptibility to hepatocellular carcinoma, Carcinogenesis, vol.32, pp.530-536, 2011.

X. D. Long, J. G. Yao, Y. Z. Huang, X. Y. Huang, F. Z. Ban et al., DNA repair gene XRCC7 polymorphisms (rs#7003908 and rs#10109984) and hepatocellular carcinoma related to AFB1 exposure among Guangxi population, China, Hepatol Res, vol.41, pp.1085-1093, 2011.

S. W. Jung, N. H. Park, J. W. Shin, B. R. Park, C. J. Kim et al., Polymorphisms of DNA repair genes in Korean hepatocellular carcinoma patients with chronic hepatitis B: possible implications on survival, J Hepatol, vol.57, pp.621-627, 2012.

H. Zhang, Y. Zhai, Z. Hu, C. Wu, J. Qian et al., Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers, Nat Genet, vol.42, pp.755-758, 2010.

V. Kumar, N. Kato, Y. Urabe, A. Takahashi, R. Muroyama et al., Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma, Nat Genet, vol.43, pp.455-458, 2011.

K. Y. Chan, C. M. Wong, J. S. Kwan, J. M. Lee, K. W. Cheung et al., Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection, PLoS One, vol.6, p.28798, 2011.

S. B. Cantor and G. S. , Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1, Future Oncol, vol.7, pp.253-261, 2011.

R. M. Brosh and S. B. Cantor, Molecular and cellular functions of the FANCJ DNA helicase defective in cancer and in Fanconi anemia, Front Genet, vol.5, p.372, 2014.

S. Cantor, R. Drapkin, F. Zhang, Y. Lin, J. Han et al., The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations, Proc Natl Acad Sci U S A, vol.101, pp.2357-2362, 2004.

S. B. Cantor, D. W. Bell, S. Ganesan, E. M. Kass, R. Drapkin et al., BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function, Cell, vol.105, pp.149-160, 2001.

A. M. Ali, T. R. Singh, and A. R. Meetei, FANCM-FAAP24 and FANCJ: FA proteins that metabolize DNA, Mutat Res, vol.668, pp.20-26, 2009.

X. Yu, C. C. Chini, M. He, G. Mer, and J. Chen, The BRCT domain is a phospho-protein binding domain, Science, vol.302, pp.639-642, 2003.

J. Xie, R. Litman, S. Wang, M. Peng, G. S. Rooney et al., Targeting the FANCJ-BRCA1 interaction promotes a switch from recombination to poleta-dependent bypass, Oncogene, vol.29, pp.2499-2508, 2010.

A. N. Suhasini and R. M. Brosh, Mechanistic and biological aspects of helicase action on damaged DNA, Cell Cycle, vol.9, pp.2317-2329, 2010.

A. N. Suhasini, J. A. Sommers, P. A. Muniandy, Y. Coulombe, S. B. Cantor et al., Fanconi anemia group J helicase and MRE11 nuclease interact to facilitate the DNA damage response, Mol Cell Biol, vol.33, pp.2212-2227, 2013.

B. P. Alter, Cancer in Fanconi anemia, Cancer, vol.97, pp.425-440, 1927.

C. Masserot-lureau, N. Adoui, F. Degos, C. De-bazelaire, J. Soulier et al., Incidence of liver abnormalities in Fanconi anemia patients, Am J Hematol, vol.87, pp.547-549, 2012.

M. Sherman, K. M. Peltekian, and C. Lee, Screening for hepatocellular carcinoma in chronic carriers of hepatitis B www.impactjournals.com/oncotarget virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population, Hepatology, vol.22, pp.432-438, 1995.

M. Peng, R. Litman, J. Xie, S. Sharma, R. M. Brosh et al., The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells, EMBO J, vol.26, pp.3238-3249, 2007.

G. Hall, A. Clarkson, A. Shi, E. Langford, H. Leung et al., Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma, Pathology, vol.42, pp.409-413, 2010.

A. Kato, N. Sato, T. Sugawara, K. Takahashi, M. Kito et al., Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients, Am J Surg Pathol, vol.40, pp.770-776, 2016.

W. Zou, X. Ma, W. Hua, B. Chen, Y. Huang et al., BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity, Oncol Lett, vol.11, pp.551-558, 2016.

C. Zhao, J. Takita, Y. Tanaka, M. Setou, T. Nakagawa et al., Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta, Cell, vol.105, pp.587-597, 2001.

W. S. Bush and J. H. Moore, Genome-wide association studies, PLoS Comput Biol, vol.11, p.1002822, 2012.

J. Long, Q. Cai, H. Sung, J. Shi, B. Zhang et al., Genome-wide association study in east Asians identifies novel susceptibility loci for breast cancer, PLoS Genet, vol.8, p.1002532, 2012.

Y. R. Li and B. J. Keating, Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations, Genome Med, vol.6, p.91, 2014.

F. Rousset, Exegeses on maximum genetic differentiation, Genetics, vol.194, pp.557-559, 2013.

M. A. Beaumont and R. A. Nichols, Evaluating loci for use in the genetic analysis of population structure, Proceedings of the Royal Society of London B: Biological Sciences, vol.263, pp.1619-1626, 1996.

T. A. Pearson and T. A. Manolio, How to interpret a genome-wide association study, JAMA, vol.299, pp.1335-1344, 2008.

E. Trepo, P. Nahon, G. Bontempi, L. Valenti, E. Falleti et al., Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data, Hepatology, vol.59, pp.2170-2177, 2014.

A. Palagyi, K. Neveling, U. Plinninger, A. Ziesch, B. S. Targosz et al., Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents, Mol Cancer, vol.9, p.127, 2010.

A. Gabrielson, A. A. Tesfaye, J. L. Marshall, M. J. Pishvaian, B. Smaglo et al., Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma, Cancer Chemother Pharmacol, vol.76, pp.1073-1079, 2015.

C. E. Strom and T. Helleday, Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy, Biomolecules, vol.2, pp.635-649, 2012.

T. Walsh, S. Casadei, M. K. Lee, C. C. Pennil, A. S. Nord et al., Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing, Proc Natl Acad Sci U S A, vol.108, pp.18032-18037, 2011.

C. Guillot, V. Favaudon, Z. Herceg, C. Sagne, S. Sauvaigo et al., PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models, BMC Cancer, vol.14, p.603, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-01122364

J. Mateo, S. Carreira, S. Sandhu, S. Miranda, H. Mossop et al., DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer, N Engl J Med, vol.373, pp.1697-1708, 2015.

J. B. Fan, K. L. Gunderson, M. Bibikova, J. M. Yeakley, J. Chen et al., Illumina universal bead arrays, Methods Enzymol, vol.410, pp.57-73, 2006.

G. R. Abecasis, A. Auton, L. D. Brooks, M. A. Depristo, R. M. Durbin et al.,

, 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes, Nature, vol.491, pp.56-65, 2012.

S. B. Gabriel, S. F. Schaffner, H. Nguyen, J. M. Moore, J. Roy et al., The structure of haplotype blocks in the human genome, Science, vol.296, pp.2225-2229, 2002.

B. Devlin, K. Roeder, and L. Wasserman, Analysis of multilocus models of association, Genet Epidemiol, vol.25, pp.36-47, 2003.

R. C. Lewontin, The Interaction of Selection, Linkage. I. General Considerations; Heterotic Models, Genetics, vol.49, pp.49-67, 1964.

Y. Wu, J. A. Sommers, A. N. Suhasini, T. Leonard, J. S. Deakyne et al., Fanconi anemia group J mutation abolishes its DNA repair function by uncoupling DNA translocation from helicase activity or disruption of protein-DNA complexes, Blood, vol.116, pp.3780-3791, 2010.